Honasa buys 58% of Fluence Pharma, launches Honasa Health to enter nutraceuticals

Mamaearth parent Honasa Consumer acquires majority stake in Fluence Pharma, forming subsidiary Honasa Health to push into nutraceuticals and beauty-from-within. Fluence clocked Rs 40 cr revenue with 20%+ EBITDA margin in FY26, marking Honasa's first diversification beyond beauty and personal care.

— FiledWed, 24 Jun, 2026, 19:43 IST·First seen Wed, 24 Jun, 2026, 19:42 IST·Source Moneycontrol · News Web

What happened

Honasa Consumer, parent of Mamaearth, acquired 58% of Fluence Pharma to enter nutraceuticals and beauty-from-within, launching subsidiary Honasa Health. Fluence

Key facts

  • 58% stake
  • Rs 40 crore revenue FY26
  • EBITDA margin >20%

Why this matters

58% majority structure with founder skin-in-the-game is the template to watch—expect Honasa to keep bolting on sub-Rs 100 cr profitable adjacencies rather than chasing transformational deals.

What to watch

  • Honasa Health revenue disclosure in quarterly results
  • New SKU launches under Honasa Health master brand
  • Competitive response from Power Gummies, Wellbeing Nutrition, HealthKart
  • Remaining 42% Fluence stake acquisition timeline
  • Margin trajectory of consolidated Honasa as nutra mix grows
  • Launch co-branded Mamaearth x Honasa Health collagen/biotin SKUs within 2 quarters
  • Expand Fluence distribution from pharma channel into Nykaa, Amazon, quick-commerce
  • Hire nutraceutical category head and scientific advisory board to build credibility
  • Earmark 15-20% of FY27 ad budget for new vertical seeding

Also reported by